Oramed Pharmaceuticals (ORMP) Change in Acquisitions & Divestments (2010 - 2026)

Oramed Pharmaceuticals has reported Change in Acquisitions & Divestments for 16 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 216.88% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $41.5 million (down 17.68% YoY), and the FY2025 full-year result was $39.6 million, down 38.66% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $2.8 million, up from -$10.9 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $124.2 million in Q3 2022, with the low at -$56.6 million in Q3 2024.
• Historically, Change in Acquisitions & Divestments has averaged $17.1 million across 5 years, with a median of $2.4 million in 2022.
• The largest YoY upside for Change in Acquisitions & Divestments was 4530.99% in 2024 against a maximum downside of 8815.38% in 2024.
• Oramed Pharmaceuticals' Change in Acquisitions & Divestments stood at $50.2 million in 2022, then tumbled by 96.76% to $1.6 million in 2023, then soared by 1592.31% to $27.5 million in 2024, then sank by 139.58% to -$10.9 million in 2025, then soared by 125.53% to $2.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $2.8 million (Q1 2026), -$10.9 million (Q4 2025), and $49.4 million (Q3 2025), per Business Quant data.